What is Restor3d?
Headquartered in Durham, North Carolina, Restor3d specializes in the development of patient-specific implants that utilize advanced biomedical materials. The company integrates 3D printing, kinematic modeling, and AI-driven design tools to provide surgeons with superior anatomical fit and integrative properties. By bridging the gap between complex surgical requirements and manufacturing precision, Restor3d is effectively transforming the standard of care for musculoskeletal reconstruction and repair.
How much funding has Restor3d raised?
Restor3d has raised a total of $324.1M across 7 funding rounds:
Unspecified
$4.3M
Other Financing Round
$23M
Private Equity
$15M
Series A
$55M
Multiple Rounds
$226.8M
Unspecified (2020): $4.3M, investors not publicly disclosed
Other Financing Round (2022): $23M, investors not publicly disclosed
Private Equity (2024): $15M supported by Trinity Capital
Series A (2024): $55M featuring Summers Value Partners
Other Financing Round (2025): $38M backed by Summers Value Partners and Trinity Capital
Stock/Share Issuance (2025): $84.8M, investors not publicly disclosed
Private Equity (2025): $104M led by Partners Group
Key Investors in Restor3d
Partners Group
Partners Group is a global private market investment manager, serving institutional investors. The company is headquartered in Zugerstrasse, Switzerland, and focuses on building private market solutions through tailored mandates and evergreen funds.
Summers Value Partners
Summers Value Partners is a boutique investment manager based in Denver, Colorado, specializing in concentrated value investing in small-cap companies within the healthcare sector.
Trinity Capital
Trinity Capital is a leading provider of diversified financial solutions, focusing on growth-stage companies through venture debt and equity investments.
What's next for Restor3d?
With the recent influx of capital, Restor3d is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its AI-based planning software and the expansion of its biomedical material portfolio. The company is expected to focus on scaling its manufacturing capabilities to meet the rising demand for personalized surgical solutions. As it moves into this next phase of enterprise-level growth, the firm will likely prioritize strategic partnerships and clinical validation to further penetrate the competitive medical device market, ensuring that its technological advancements translate into improved patient outcomes and long-term operational efficiency.
See full Restor3d company page
